IL272064A - Binding proteins 1 - Google Patents

Binding proteins 1

Info

Publication number
IL272064A
IL272064A IL272064A IL27206420A IL272064A IL 272064 A IL272064 A IL 272064A IL 272064 A IL272064 A IL 272064A IL 27206420 A IL27206420 A IL 27206420A IL 272064 A IL272064 A IL 272064A
Authority
IL
Israel
Prior art keywords
binding proteins
proteins
binding
Prior art date
Application number
IL272064A
Other languages
English (en)
Hebrew (he)
Inventor
James Campbell
Valentina Dubljevic
James Hansen
Zahra Rattray
Jiangbing Zhou
Original Assignee
Nucleus Therapeutics Pty Ltd
Univ Yale
James Campbell
Valentina Dubljevic
James Hansen
Zahra Rattray
Jiangbing Zhou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nucleus Therapeutics Pty Ltd, Univ Yale, James Campbell, Valentina Dubljevic, James Hansen, Zahra Rattray, Jiangbing Zhou filed Critical Nucleus Therapeutics Pty Ltd
Publication of IL272064A publication Critical patent/IL272064A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL272064A 2017-07-17 2020-01-15 Binding proteins 1 IL272064A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762533546P 2017-07-17 2017-07-17
US201762596694P 2017-12-08 2017-12-08
PCT/US2018/042532 WO2019018426A1 (en) 2017-07-17 2018-07-17 BINDING PROTEINS 1

Publications (1)

Publication Number Publication Date
IL272064A true IL272064A (en) 2020-03-31

Family

ID=65015294

Family Applications (1)

Application Number Title Priority Date Filing Date
IL272064A IL272064A (en) 2017-07-17 2020-01-15 Binding proteins 1

Country Status (8)

Country Link
US (5) US11613590B2 (enExample)
EP (1) EP3655432A4 (enExample)
JP (2) JP7690285B2 (enExample)
CN (1) CN111094338A (enExample)
AU (1) AU2018302110B2 (enExample)
CA (1) CA3070252A1 (enExample)
IL (1) IL272064A (enExample)
WO (2) WO2019018428A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6178785B2 (ja) 2011-04-01 2017-08-09 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 細胞浸透性抗ｄｎａ抗体およびｄｎａ修復を阻害するためのその使用
US11590242B2 (en) 2016-06-15 2023-02-28 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
WO2017218824A1 (en) 2016-06-15 2017-12-21 Yale University Anti-guanosine antibody as a molecular delivery vehicle
WO2019152806A1 (en) * 2018-02-01 2019-08-08 Yale University Compositions and methods for enhancing nuclear translocation
KR20210053930A (ko) 2018-08-31 2021-05-12 예일 유니버시티 공여자 올리고뉴클레오티드 기반의 유전자 편집을 향상시키기 위한 조성물 및 방법
WO2020047345A1 (en) * 2018-08-31 2020-03-05 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
WO2021042060A1 (en) 2019-08-30 2021-03-04 Yale University Compositions and methods for delivery of nucleic acids to cells
JP2023544970A (ja) 2020-08-31 2023-10-26 イエール ユニバーシティ 細胞への核酸の送達のための組成物及び方法
CN117295753A (zh) 2020-12-04 2023-12-26 基那奥生物公司 用于将核酸递送到细胞的组合物和方法
KR20230154921A (ko) 2021-03-03 2023-11-09 예일 유니버시티 골격근 질환을 치료하기 위한 조성물 및 방법
US20240226316A1 (en) * 2021-05-25 2024-07-11 Transmab Pty Ltd Improved immunoglobulin I
US20240226311A1 (en) * 2021-05-25 2024-07-11 Transmab Pty Ltd Improved immunoglobulin II
EP4362984A1 (en) 2021-07-02 2024-05-08 Yale University Compositions and methods for treating cancers
WO2023034864A1 (en) 2021-08-31 2023-03-09 Yale University Compositions and methods for treating cancers
AU2022414095A1 (en) * 2021-12-15 2024-08-01 The Trustees Of Indiana University Cell targeting compositions and methods
EP4486440A1 (en) 2022-03-03 2025-01-08 Yale University Compositions and methods for treating disease
WO2023168427A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
IL315254A (en) * 2022-03-03 2024-10-01 Univ Yale Human 3E10 antibodies, variants and antigen-binding fragments thereof
EP4584292A1 (en) 2022-09-09 2025-07-16 Yale University Proteolysis targeting antibodies and methods of use thereof
CN120787163A (zh) 2022-12-27 2025-10-14 耶鲁大学 抗体药物缀合物
EP4655007A1 (en) 2023-01-23 2025-12-03 Yale University Antibody oligonucleotide conjugates
WO2024197302A1 (en) 2023-03-23 2024-09-26 Yale University Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping
WO2025049905A1 (en) 2023-09-01 2025-03-06 Gennao Bio, Inc. Dnase co-expression in host cells
WO2025090121A1 (en) * 2023-10-27 2025-05-01 Yale University Conjugate and methods of treatment
WO2025097000A1 (en) 2023-11-01 2025-05-08 Yale University Antibody-based methods for treating polycystic kidney disease
CN117924516B (zh) * 2024-01-02 2025-07-01 河北神宇生物技术有限公司 一种提高adc药物疗效的重组蛋白及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
WO2013138662A1 (en) 2012-03-16 2013-09-19 4S3 Bioscience, Inc. Antisense conjugates for decreasing expression of dmpk
US9283272B2 (en) * 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
EP3711820A1 (en) * 2014-01-13 2020-09-23 Valerion Therapeutics, LLC Internalizing moieties
US10040867B2 (en) 2014-03-04 2018-08-07 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
CA2989294A1 (en) * 2014-06-13 2015-12-17 Valerion Therapeutics, Llc Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
CA2995673A1 (en) 2014-08-27 2016-03-03 Valerion Therapeutics, Llc Internalizing moieties for treatment of cancer
EP3194450A1 (en) * 2014-08-28 2017-07-26 Yale University Multivalent fragments of antibody 3e10 and methods of use thereof
US10383945B2 (en) 2015-02-18 2019-08-20 The United States of America as Represented by the Department of Verterans Affairs Methods for DNA-dependent targeting of a cell permeant antibody

Also Published As

Publication number Publication date
US20240052063A1 (en) 2024-02-15
CN111094338A (zh) 2020-05-01
US20230406960A1 (en) 2023-12-21
CA3070252A1 (en) 2019-01-24
US20200216568A1 (en) 2020-07-09
JP2020527355A (ja) 2020-09-10
US20200216567A1 (en) 2020-07-09
JP2023083385A (ja) 2023-06-15
US11613590B2 (en) 2023-03-28
WO2019018426A1 (en) 2019-01-24
AU2018302110A1 (en) 2020-02-06
WO2019018428A1 (en) 2019-01-24
US20250376540A1 (en) 2025-12-11
JP7690285B2 (ja) 2025-06-10
EP3655432A1 (en) 2020-05-27
AU2018302110B2 (en) 2024-11-21
EP3655432A4 (en) 2021-04-14
US12312417B2 (en) 2025-05-27

Similar Documents

Publication Publication Date Title
IL272064A (en) Binding proteins 1
IL298286B2 (en) Bispecific binding proteins and their uses
IL272643A (en) Binders
SG10202107880XA (en) Mesothelin binding proteins
GB201802201D0 (en) Binding agents
PT3568022T (pt) Proteínas inseticidas
SG11202001420VA (en) Modular binding proteins
GB201608197D0 (en) Novel proteins
IL268288A (en) Binders
DK3737402T3 (en) Modificeret protein
SG10201912051TA (en) Cd131 binding proteins and uses thereof
ZA201901862B (en) Modified factor h binding protein
GB2558968B (en) G Proteins
IL304317A (en) tgf–beta–rii binding proteins
ZA202003722B (en) Modified globin proteins
IL269477A (en) Polypeptides that bind to IL-1R-1
ZA201906821B (en) Anti-jagged1 antigen binding proteins
SG11202106393SA (en) Pseudofab-based multispecific binding proteins
ZA201905544B (en) Modified haemoglobin proteins
GB201615588D0 (en) TSLP Binding Proteins
GB201614627D0 (en) Antigen binding proteins
GB201703049D0 (en) Single-strand binding protein
HK40018957A (en) Binding proteins 1
GB201919286D0 (en) Binding proteins
IL266419A (en) Binding peptides